Eine Studie zu Atezolizumab plus Bevacizumab im Vergleich zu aktiver Überwachung als adjuvante Therapie bei Patient*innen mit hepatozellulärem Karzinom und einem hohen Risiko eines HCC-Rezidivs

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  • Krebs
  • Hepatozelluläres Karzinom (HZK)
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:

Aktiv, keine Rekrutierung

Diese Studie läuft in
Städte
  • Bonn
  • Frankfurt am Main
  • Regensburg
  • Ulm
Studien-ID:

NCT04102098 2019-002491-14 2023-504303-86-00 WO41535

      Studienzentren finden

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden für Laien bearbeitet.

      Die folgenden Informationen stammen aus der öffentlich zugänglichen Website ClinicalTrials.gov und werden nicht geändert.

      Results Disclaimer

      Studienzusammenfassung

      This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT04102098, WO41535, 2019-002491-14, 2023-504303-86-00 Studien-ID
      Atezolizumab, Bevacizumab Treatments
      Carcinoma, Hepatocellular Condition
      Official Title

      A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

      Einschlusskriterien

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants with a first diagnosis of HCC who have undergone a curative resection or ablation (radiofrequency ablation [RFA] or microwave ablation [MVA] only)
      • Documented diagnosis of HCC that has been completely resected or ablated (RFA or MVA only)
      • Absence of major macrovascular invasion (except Vp1/Vp2) and extrahepatic spread
      • Full recovery from surgical resection or ablation within 4 weeks prior to randomization
      • High risk for HCC recurrence after resection or ablation
      • For patients who received post-operative transarterial chemoembolization: full recovery from the procedure within 4 weeks prior to randomization
      • For patients with resected HCC, availability of a representative baseline tumor tissue sample
      • ECOG Performance Status of 0 or 1
      • Child-Pugh Class A status
      • Adequate hematologic and end-organ function
      • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods
      • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm
      Exclusion Criteria
      • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
      • Recurrent HCC prior to randomization
      • Evidence of residual, recurrent, or metastatic disease at randomization
      • Clinically significant ascites
      • History of hepatic encephalopathy
      • Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization
      • Have received more than 1 cycle of adjuvant TACE following surgical resection
      • Active or history of autoimmune disease or immune deficiency
      • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
      • Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1, unstable arrhythmia, or unstable angina
      • History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
      • Active tuberculosis
      • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
      • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to Day 1 of Cycle 1.
      • Co-infection with HBV and HCV.
      • Uncontrolled or symptomatic hypercalcemia
      • Any treatment for HCC prior to resection or ablation, including systemic therapy and locoregional therapy such as TACE
      • Treatment with systemic immunostimulatory or immunosuppressive agents
      • Inadequately controlled arterial hypertension
      • History of hypertensive crisis or hypertensive encephalopathy
      • Significant vascular disease
      • Evidence of bleeding diathesis or significant coagulopathy
      • Current or recent use of aspirin or full-dose oral or parenteral anticoagulants
      • Core biopsy within 3 days of Day 1 of Cycle 1
      • History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess
      • Serious non-healing or dehiscing wound
      • Major surgical procedure within four weeks
      • Chronic daily treatment with a non-steroidal anti-inflammatory drug

      Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de

       

      Über klinische Studien

      Erfahren Sie mehr über klinische Studien und wie sie durchgeführt werden

      Erfahren Sie mehr